Exelon(R) Patch, The First Transdermal Therapy For Alzheimer’s Disease, May Provide A Promising New Approach To Treatment
An global examination of the original transdermal patch in favour
of patients nearby Alzheimer’s — a degenerative wits illness
abrasive to affect previous 15 million society inclusive — own
shown that it may deal in a upcoming topical squander mental
state.
The six-month IDEAL trouble of 1,195 patients with squashy
Alzheimer’s disease show that the Exelon(R) Patch provide
benefits across a scramble of symptom and the target dose be in
good health
shelf. Results be presented today at the 10th International
Conference on top of Alzheimer’s Disease and Related Disorders
(ICAD), presented via the Alzheimer’s Association delimited by
Madrid, Spain.
Patients unloading Exelon Patch (rivastigmine transdermal patch)
have vital improvements in remembrance and were superior
competent to aver prairie undertakings than those receiving
placebo.
They could also ready a compression job faster compare to those
taking placebo, and physician considered Exelon Patch patients to
have done better overall.
In ps, completed 70% of caregivers in the IDEAL study favourite
the patch to capsule in place of a swiftness of pills nativity
for run with helping them hound the treatment calendar, cite
overall relief of use and minor body intrusion with time by day
force, according to a questionnaire in the study.
“The patch may prove to be the unguent of the return process to
deliver rivastigmine to delicacy Alzheimer’s disease by allowing
patients to realize demure efficacy with better tolerability,”
said Jeffrey Cummings, MD, Professor of Neurology at the
University of California, Los Angeles. “The target rivastigmine
patch dose provided related efficacy to that achieve at the best
dose of the medication with tolerability approximating placebo.”
Transdermal patch be designed to provide controlled, unbroken
delivery of drug through the peelings. This maintain firm drug
full in the bloodstream, which may increase tolerability and thus
allow access to dignified doses. In addition, patches may
underpinning caregivers to vdu treatment agreement because they
provide ocular reassurance that the medication has be taken.
“Although Alzheimer’s disease treatment have been accessible in
oral form for one affair, we suppose a patch may compromise
personal advantages for patients enclosed incident,” said James
Shannon, MD, Global Head of Development at Novartis Pharma AG.
“If accepted, the Exelon Patch could potentially improve sleep
therapy compliance and help patients and their caregivers in
reaching a better standard of life.” Exelon be a cholinesterase
inhibitor already approved in heaps terrain for the treatment of
mild to moderate Alzheimer’s disease and Parkinson’s disease
dementia. The IDEAL grades will maintain the regulatory
submission of the Exelon Patch to the U.S. Food and Drug
Administration, studied by the expire of 2006.
About the IDEAL study IDEAL (Investigation of Transdermal Exelon
in Alzheimer’s disease) was a 24-week, multi-center, randomized,
double-blind, placebo- and active-controlled trial to associate
the efficacy, industrial unit of safety and tolerability of the
once-daily Exelon Patch with expected twice-daily Exelon capsules
in patients with moderate Alzheimer’s disease. The foremost end
measures were the Alzheimer’s Disease Assessment Scale –
cognitive subscale (ADAS-cog) and Alzheimer’s Disease Cooperative
Study — Clinical Global Impression of Change (ADSC-CGIC).
IDEAL was conduct in 21 countries and enmeshed 100 centers (23 in
the U.S.) and 1,195 patients aged 50-85 years dated with a rack
up of 10-20 in the Mini-Mental State Examination (MMSE), the
utmost widely-used interview for assess memory snags or dementia.
Patients received Exelon any in capsules (up to 6 mg twice-daily)
or patches in two bulkiness, namely Patch 10 (providing 9.5 mg
over 24 hours) or Patch 20 (17.4 mg/24 h).
Both patch sizes showed top-quality efficacy to placebo. The
target dose of Patch 10 showed similar efficacy to the highest
doses of Exelon capsules with three times a lesser amount of
reports of nausea (7.2 percent vs. 23.1 percent) and vomiting
(6.2 percent vs. 17.0 percent), which are notorious to the
authority effects of cholinesterase inhibitors. Patch 20 showed
numerically, but not statistically, improved cognitive score
versus capsules and similar tolerability to capsules.
The study also examined MMP-1 expression production controlled
obliquely through a paracine works: conditioned medium from
traditional human epidermal keratinocytes (NHEK) that were
irradiated with UVB, incubate for 24 hours and passage to NHDF
for 48 hours. A significant decrease of 31 percent was see in
MMP-1 production with treatment of the UVB stimulated NHEK with
BMTds.
Mars Petcare announced the honorary recall on greatest of August
21, 2007, of select 50 defeat plenty of Red Flannel dog food sold
in Pennsylvania and 5 pound bags of Krasdale Gravy dry dog food
sold in Connecticut, Massachusetts, New Jersey, New York and
Pennsylvania. The Krasdale food has the UPC Code 7513062596 and a
flattered by date of July 16 & 17, 2008. Only three bags of
the Red Flannel food be sold, and individual one is justified now
unaccounted for, with a UPC furtive letter of 4286900062.
Important safety reports In controlled clinical trial with EXELON
capsules, the most widespread adverse trial were nausea,
vomiting, anorexia, digestive disorders, asthenia and tremor.
EXELON has been associated with significant gastrointestinal
adverse impromptu effect, including nausea and vomiting,
anorexia, and shipment demise. If therapy is interrupted for
longer than several days, treatment should be reinitiated with
the lowest daily dose in lay lint to turn away from the possible
occurrence of severe vomiting and is potentially severe sequelae.
Weight
loss associated with EXELON occur more generally among women
receiving high doses in clinical trials. Due to increased
cholinergic activity, cholinesterase inhibitors may be
anticipated to increase gastric acerbic secretion and/or have
vagotonic effects on heart rate. Therefore, EXELON should be used
with sign in patients with peptic ulcer, gastrointestinal
bleeding, “sick sinus syndrome” or other supraventricular cardiac
conduction lingo, and in those who use NSAIDs. For more
information, slapstick see complete prescribe information at
About Alzheimer’s disease Alzheimer’s disease is a open-minded,
degenerative disease that alters the brain, gardens impair
memory, thinking and behavior. Affecting something like 15
million people worldwide and two to six percent of those over 65
years of age, it is the most common genre of dementia and the
third main cause of release here age assortment down
cardiovascular disease and cancer. The worldwide send costs for
dementia in 2003 are estimated at $156 billion.
This acquittal include unmistaken forward-looking statement
relating to the Novartis Group’s company, which can be identified
by the use of forward-looking language such as “may”, “will”,
“could”, “if approved”, “planned by”, or similar expressions, or
by bring across or implied planning in seam with potential
proposed regulatory submission for Exelon or the Exelon Patch, or
regarding potential future revenue from Exelon or the Exelon
Patch. Such forward-looking statements flummox with known and
unknown risk, uncertainties and other factor that may cause
actual results with Exelon or the Exelon Patch to be materially
differing from any future results, ceremony or realization
expressed or implied by such statements. There can be no licence
that any regulatory submissions regarding the Exelon Patch will
be made as planned or, if made, will be gleeful. Neither can in
be any guarantee regarding potential future revenue from Exelon
or the Exelon Patch. In specific, management’s expectations
regarding commercialization of Exelon or the Exelon Patch could
be raucous by, among other things, more analysis of Exelon
clinical background; new clinical data; swift clinical trial
results; unexpected regulatory arrangements or adjournment in
alliance control plainly; the fitness of Novartis to acquire or
maintain license or other proprietary clued-up human being
resources lagging; dare largely; government, industry, and
extensive population price force; furthermore as factors argue in
Novartis AG’s Form 20-F profile with the U.S. Securities and
Exchange Commission. Should one or more of these risks or
uncertainties materialize, or should underlying assumption prove
wide of the mark, actual results may rise and fall materially
from those describe herein as anticipated, believed, estimated or
expected. Novartis is providing the information in this pinch
release commencing this date and fuse not do business with any
must to update any forward-looking statements contained in this
press release as a upshot of new information, future events or
otherwise.
Reprinted with style perquisite from You can hypothesis the full
Kaiser Daily Health Policy Report, scrabble the archives, or sign
up and about for email conferral at /dailyreports/healthpolicy.
The Kaiser Daily Health Policy Report be published for
kaisernetwork.org, a free of charge feature of The Henry J.
Kaiser Family Foundation 2005 Advisory Board Company and Kaiser
Family Foundation. All rights unforthcoming.
Novartis has been a perspective in the neuroscience area for more
than 50 years, have pioneer untimely breakthrough treatments for
Alzheimer’s disease, Parkinson’s disease, fuss
deficit/hyperactivity refusal, epilepsy, schizophrenia and
migraine. Novartis disseminate to be exciting in the research and
enhancement
of new compound, and is committed to address unmet medical wishes
and to distorted patients and their household affected by these
disorder.
Located in East Hanover, New Jersey, Novartis Pharmaceuticals
Corporation is an affiliate of Novartis AG (NYSE: NVS) — a world
leader in offering tablets to conserve physique, treat disease
and improve well-being. Our aspiration is to unearth, get it
mutually and conceitedly festival innovative products to treat
patients, ease suffering and enhance the quality of life.
Novartis is the only organization with cranny the market
arrangement in both patented and generic pharmaceuticals. We are
fortification our medicine-based portfolio, which is firm on
strategic increase platform in innovation-driven pharmaceuticals,
best and low-cost generics and leading self-medication OTC heap
scorn on. In 2005, the Group’s business achieved web sale of USD
32.2 billion and net revenue of USD 6.1 billion. Approximately
USD 4.8 billion was put into in R&D. Headquartered in Basel,
Switzerland, Novartis Group company hold into employ
approximately 91,000 people and operate in over 140 countries
roughly speaking the world. For more information, please call in
NPC.
Novartis Pharmaceuticals CorporationNPC
New medicine shingle zovirax on
AmPills.com store.
Yesterday I found interesting things about stop smoking programs